Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02735343
Other study ID # FWH20160057H
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date August 2016
Est. completion date May 2017

Study information

Verified date February 2024
Source Mike O'Callaghan Military Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators are comparing Ketamine to prochlorperazinecompazine for benign headaches in the ED. Subjects will be randomized into 1 of 2 groups. Group 1 will receive standard treatment of prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV. Group 2 (research arm) will receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. Subjects will be seen at 15, 30, 45, and 60 minutes post-intervention to obtain Heart Rate, Blood Pressure, Headache severity, Nausea severity, Vomiting severity, Anxiety severity, and Restlessness severity. At 24-48 hours post intervention we will contact subjects and assess their pain and assess their satisfaction with their migraine pain management as part of this study. Subjects' participation will last up to 48 hours post headache.


Description:

Screening Visit: - Obtain signed Informed Consent Document and HIPAA Authorization (research-driven). - Record: Date of birth, age, phone number, gender, race, ethnicity, social security number, name of standard of care rescue medications (over-the-counter and prescription), current email address (to be used for scheduling only), height (in inches), weight (in pounds), history of traumatic brain injury, concussion, or any mild to severe head trauma, medication use. (research only) - Review past medical history in Armed Forces Health Longitudinal Technology Application (AHLTA) or ESSENTRIS to verify the inclusion/exclusion criteria. - Women of childbearing potential will have a serum pregnancy test (5-10 milliliters (mls), approximately 1-2 teaspoons of blood) (research-driven). Visit 1: - Heart rate - Blood pressure - Headache severity via 100-mm VAS. - Nausea severity via 100-mm VAS. - Vomiting severity via 100-mm VAS. - Anxiety severity via 100-mm VAS. - Restlessness severity via 100-mm VAS. - Record type and amount of rescue medications (over-the-counter and prescription) use in the past 7 days. (research only) - Subjects will be randomized by the pharmacy. We will use a random-number generator and use blocking to ensure roughly equal sample sizes. Both subjects and investigators will be blinded to the study group assignments. Subjects will be randomized by the pharmacy into one of two groups (research-driven): - Group 1: Standard treatment arm (prochlorperazinecompazine 10 mg IV along with diphenhydramine 25 mg IV) - Group 2: Research arm (Ketamine 0.3 mg/kg along with ondansetron 4 mg IV) 15 minutes post treatment: - Heart rate - Blood pressure - Headache severity via 100-mm VAS. - Nausea severity via 100-mm VAS. - Vomiting severity via 100-mm VAS. - Anxiety severity via 100-mm VAS. - Restlessness severity via 100-mm VAS. 30 minutes post treatment: - Heart rate - Blood pressure - Headache severity via 100-mm VAS. - Nausea severity via 100-mm VAS. - Vomiting severity via 100-mm VAS. - Anxiety severity via 100-mm VAS. - Restlessness severity via 100-mm VAS. 45 minutes post treatment: - Heart rate - Blood pressure - Headache severity via 100-mm VAS. - Nausea severity via 100-mm VAS. - Vomiting severity via 100-mm VAS. - Anxiety severity via 100-mm VAS. - Restlessness severity via 100-mm VAS. 60 minutes post treatment: - Heart rate - Blood pressure - Headache severity via 100-mm VAS. - Nausea severity via 100-mm VAS. - Vomiting severity via 100-mm VAS. - Anxiety severity via 100-mm VAS. - Restlessness severity via 100-mm VAS. 24-48 hours post treatment: - Subjects will be contacted either in-person or via phone and the following information will be collected: - Subjects will be asked "On a scale of 0-10, with 10 being the worst pain, what is your current level of pain?" - Subjects will be asked "On a scale of 0 to 10, how satisfied were you with you're the migraine pain management as part of this research study? (dissatisfied 0 - 10 very satisfied) - Subjects will be alerted to what group they were randomized into.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY. Inclusion Criteria - Age 18 to 65 years who present to the ED with complaint of a headache - Temperature less than 100.4 F - Diastolic blood pressure less than 104 mm Hg - Normal neurologic exam and normal mental status Exclusion Criteria - Pregnant or breastfeeding - Meningeal signs are present - Acute angle closure glaucoma is suspected - Head trauma within the previous two weeks - Lumbar puncture within the previous two weeks - Thunderclap (rapid) onset of the headache - Weight more than 150 kg or less than 40 kg - Known allergy to diphenhydramine - Known allergy to ondansetron. (Zofran) - Known allergy to Compazine - Known allergy to Ketamine - History of schizophrenia or bipolar disorder - History of intracranial hypertension - Is a prisoner - Patient declined informed consent - Non-English speaking patient - Attending provider excludes patient - Elderly patients with dementia - Patients with severe headaches that diminish their decision making capability will not be able to participate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Compazine
Compazine 10mg with diphenhydramine 25 mg IV
Ketamine
Ketamine 0.3 mg/kg along with ondansetron 4 mg IV

Locations

Country Name City State
United States Mike O'Callaghan Federal Medical Center Nellis Air Force Base Nevada

Sponsors (1)

Lead Sponsor Collaborator
Mike O'Callaghan Military Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Score Subjects marked a line on a Visual Analogue Scale rating from None to Severe. Study staff measured the mark in millimeters and converted to a scale from 0 to 100 possible points, with 100 being most severe. 15 min, 30 min, 45 min, 60 min
See also
  Status Clinical Trial Phase
Withdrawn NCT03472872 - A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache Phase 4
Withdrawn NCT05410366 - Safe Harbors in Emergency Medicine, Specific Aim 3
Withdrawn NCT02866084 - Neuromodulation Treatment of Vestibular Migraines N/A
Active, not recruiting NCT03537573 - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care N/A
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Not yet recruiting NCT04352218 - Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache Phase 2
Completed NCT02734992 - Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Completed NCT01327118 - Prostaglandin F2alpha in a Human Headache Model N/A
Not yet recruiting NCT00969995 - Identification of Inflammatory Markers in Migraine Patients N/A
Not yet recruiting NCT00752921 - Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache Phase 4
Terminated NCT00291395 - PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers Phase 1
Completed NCT00212810 - Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache. Phase 4
Completed NCT00263094 - An End to the Yom Kippur (and Ramadan) Headache N/A
Completed NCT00135122 - Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache Phase 3
Completed NCT02475005 - An Intervention to Improve Adolescent Headache Self-management N/A
Completed NCT03163901 - The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury N/A
Completed NCT01664585 - Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life N/A
Completed NCT04632420 - Evaluation of Headache and Childbirth in a Chronic Pain Population
Recruiting NCT05033613 - Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease